![Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies - ScienceDirect Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737221000505-gr1.jpg)
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies - ScienceDirect
![Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-018-0304-6/MediaObjects/41416_2018_304_Fig1_HTML.png)
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer
![Cancers | Free Full-Text | Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer Cancers | Free Full-Text | Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer](https://pub.mdpi-res.com/cancers/cancers-12-03050/article_deploy/html/images/cancers-12-03050-ag-550.jpg?1603357729)
Cancers | Free Full-Text | Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer
![Novartis' new macular degeneration drug has to compete against colon cancer drug Avastin. Why? < Pharma < Article - KBR Novartis' new macular degeneration drug has to compete against colon cancer drug Avastin. Why? < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/201904/5588_5614_4157.jpg)
Novartis' new macular degeneration drug has to compete against colon cancer drug Avastin. Why? < Pharma < Article - KBR
![Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire](https://mms.businesswire.com/media/20230116005182/fr/1686347/5/Servier_Logo.jpg)
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
![Bevacizumab inhibits cell viability. Cell proliferation was analyzed by... | Download Scientific Diagram Bevacizumab inhibits cell viability. Cell proliferation was analyzed by... | Download Scientific Diagram](https://www.researchgate.net/publication/327628765/figure/fig2/AS:670385234276367@1536843703662/Bevacizumab-inhibits-cell-viability-Cell-proliferation-was-analyzed-by-MTT-in-colorectal.png)
Bevacizumab inhibits cell viability. Cell proliferation was analyzed by... | Download Scientific Diagram
![FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-020-01140-9/MediaObjects/41416_2020_1140_Fig1_HTML.png)
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
![Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial - The Lancet Oncology Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/5601cd30-c845-4b7f-a573-2a82dc465483/gr1.gif)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial - The Lancet Oncology
![Maintenance Treatment With Capecitabine and Bevacizumab Is Effective in Metastatic Colorectal Cancer - The ASCO Post Maintenance Treatment With Capecitabine and Bevacizumab Is Effective in Metastatic Colorectal Cancer - The ASCO Post](https://ascopost.com/media/5318/5305_chart.jpg)